Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
复制标题
DOI：
10.1038/s41586-020-1930-8
复制
发表时间：
2020-01-22
期刊：
影响因子：
64.8
通讯作者：
Shen, Yu
中科院分区：
文献类型：
--
作者：
Faivre, Emily J.;McDaniel, Keith F.;Shen, Yu
ABBV-744是BET家族蛋白质BD 2结构域的选择性抑制剂，在小鼠异种移植模型中对前列腺癌有效，毒性低于双溴结构域BET抑制剂ABBV-075。溴结构域和额外末端（BET）结构域家族蛋白质是表观遗传阅读器，通过其溴结构域结合乙酰化组蛋白以调节基因转录。以类似亲和力结合BRD 2、BRD 3、BRD 4和BRDt的第一（BD 1）和第二（BD 2）溴结构域的双溴结构域BET抑制剂（DbBi）在单一疗法癌症试验中显示出适度的临床活性。血液中血小板数量减少（血小板减少症）以及胃肠道毒性症状是某些类型DbBi的剂量限制性不良事件（1-5）。鉴于在小鼠中Brd 4基因沉默后观察到类似的血液学和胃肠道缺陷（6），血小板和胃肠道毒性可能代表与BET抑制相关的靶向活性。BET家族蛋白中的两个单独的布罗莫结构域可以具有不同的功能（7-9），并且在已经报道了一个或两个布罗莫结构域的药理学抑制之后具有不同的细胞表型（10，11），这表明选择性靶向布罗莫结构域之一可以导致与DbBi相比不同的功效和耐受性特征。对单个结构域具有选择性的可用化合物缺乏足够的效力和体内功效和耐受性评估所需的药代动力学性质（10-13）。在这里，我们开展了一项药物化学活动，发现了ABBV-744，这是一种具有药物样特性的BET家族蛋白BD 2结构域的高效选择性抑制剂。与DbBi诱导的广泛的细胞生长抑制相反，ABBV-744的抗增殖活性主要但不完全限于表达全长雄激素受体（AR）的急性骨髓性白血病和前列腺癌的细胞系。ABBV-744在前列腺癌异种移植物中保留了强大的活性，并且显示出比DbBi ABBV-075更少的血小板和胃肠道毒性（14）。RNA表达和染色质免疫沉淀分析，然后测序显示，ABBV-744从含AR的超级增强子中置换BRD 4，并抑制AR依赖性转录，与ABBV-075相比，对整体转录的影响较小。这些结果强调了选择性靶向BET家族蛋白的BD 2结构域用于癌症治疗的潜在价值。
ABBV-744, a selective inhibitor of the BD2 domains of BET family proteins, is effective against prostate cancer in mouse xenograft models, with lower toxicities than the dual-bromodomain BET inhibitor ABBV-075.Proteins of the bromodomain and extra-terminal (BET) domain family are epigenetic readers that bind acetylated histones through their bromodomains to regulate gene transcription. Dual-bromodomain BET inhibitors (DbBi) that bind with similar affinities to the first (BD1) and second (BD2) bromodomains of BRD2, BRD3, BRD4 and BRDt have displayed modest clinical activity in monotherapy cancer trials. A reduced number of thrombocytes in the blood (thrombocytopenia) as well as symptoms of gastrointestinal toxicity are dose-limiting adverse events for some types of DbBi(1-5). Given that similar haematological and gastrointestinal defects were observed after genetic silencing of Brd4 in mice(6), the platelet and gastrointestinal toxicities may represent on-target activities associated with BET inhibition. The two individual bromodomains in BET family proteins may have distinct functions(7-9) and different cellular phenotypes after pharmacological inhibition of one or both bromodomains have been reported(10,11), suggesting that selectively targeting one of the bromodomains may result in a different efficacy and tolerability profile compared with DbBi. Available compounds that are selective to individual domains lack sufficient potency and the pharmacokinetics properties that are required for in vivo efficacy and tolerability assessment(10-13). Here we carried out a medicinal chemistry campaign that led to the discovery of ABBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-075(14). Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.